tbuckley/cabot-search huggingface dataset:
IMPACT OF MAINTENANCE HEMODIALYSIS ON MAJOR BLEEDING RISK IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Nozomu Kanehama, Masaru Ishida, Kengo Tosaka, Masanobu Niiyama, Yorihiko Koeda, Yu Ishikawa, Yudai Shimoda, Takumi Kimura, Tomonori Itoh, Yoshihiro Morino
Journal: Journal of the American College of Cardiology (2020)
THE ABANDONED INFERIOR VENA CAVA FILTER: IS IT A BIG DEAL? IVC FILTER RETRIEVAL RATES AND CLINICAL OUTCOMES OF NON-RETRIEVAL
Authors: Jason Rauba, Ufaira Shaik, M. Fuad Jan, Suhail Allaqaband, Tanvir Bajwa, Tonga Nfor
Journal: Journal of the American College of Cardiology (2020)
Benefits of percutaneous ethanol injection in the treatment of advanced hepatocellular carcinoma.
Authors: Micheal Ayedima Misauno, Mercy Wakili Isichei
Journal: Journal of Clinical Oncology (2013)

e15119 Background: Hepatocellular carcinoma (HCC) is a devastating disease in which survival measured in months from time of diagnosis. Incidence is highest in Asia and Africa with high prevalences of hepatitis B and hepatitis C being strong predisposing factors. HCC is screened and diagnosed early in developed countries but this is not obtainable in our practice where patients present late, with severe abdominal pain and mass and therapeutic options are limited. Percutaneous ethanol injection (PEI) introduced twenty years ago for palliation of inoperable hepatocellular carcinoma is an option we are just exploring. This study was aimed at evaluating the benefits of percutaneous ethanol injection in the management of advanced hepatocellular carcinoma. Methods: With IRB clearance, informed consent was obtained from consecutive patients diagnosed with HCC. Patients with jaundice, signs of liver failure and coma were excluded from this study. They were randomized to Ethanol treatment in form of absolute alcohol manufactured by Riedel-de Haen, Germany “Group one” or routine pain control management (DF118) “Group two”. Baseline investigations and pain score using Visual Analogue Scale (VAS) was obtained for both groups. PEI was administered via ultrasound guided intra-tumour injection of 10- 50mls of ethanol at each sitting. Investigation and pain score were obtained weekly for four weeks then monthly at follow up. Data obtained from August 2010 to July 2012 was analyzed using Epi Info. Results: “Group one” 32 patients had (PEI), “Group two” 32 (DF118) out of an initial 82; 18 patients were excluded. Mean age was 40.4+/- 14.2 yrs, range of 18 to 60 yrs. Group one had 28 (87.5%) males and 4 (12.5%) females; Group two 29 (90.6%) males and 3 (9.4%) female. All patients had Right hypochondrial pain and mass. Pre intervention pain score ranged from 6-9 for both groups while post intervention pain score a week after was 1 -2 for group 1, and group 2 required regular analgesics to control their pain. Mean survival durations were 8 months and 2.5 months for groups 1 and 2, respectively. Conclusions: We conclude that percutaneous ethanol injection significantly reduces the pain of advanced hepatocellular carcinoma.
A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours
Authors: R. Hofheinz, A. Hochhaus, S. Al-Batran, A. Nanci, V. Reichardt, D. Trommeshauser, M. Hoffmann, M. Steegmaier, G. Munzert, E. Jäger
Journal: Journal of Clinical Oncology (2006)

2038 Background: BI 2536 is a novel highly potent and selective inhibitor of the serine-threonine kinase polo-like kinase 1 (Plk1), which is a key regulator of cell cycle progression. Objectives of this trial were the assessment of the maximum tolerated dose (MTD), overall safety, pharmacokinetics and efficacy of BI 2536 given intravenously. Methods: Sequential cohorts of 3 to 6 patients (pts) with pretreated advanced or metastatic solid tumours received intravenous infusions of BI 2536 on days 1 and 8 of a 3-week treatment course following a toxicity guided dose escalation design. Further treatment courses were administered to pts in the absence of disease progression and if toxicity after a 3-week treatment course had resolved. Results: A total of 42 pts was treated at doses of 25 mg (n=3), 50 mg (n=3), 100 mg (n=22), 125 mg (n=5), 150 mg (n=6) and 200 mg (n=3). Reversible CTCAE grade ≥ 3 neutropenia in 14/42 pts represented the main drug related toxicity with an incidence of 3/5 in the 125 mg cohort, 4/6 in the 150 mg and 2/2 in the 200 mg dose cohorts. Dose limiting toxicity (DLT) was defined as drug related toxicity prohibiting administration of the day 8 dose of BI 2536 (hematologic: CTCAE ≥ 3 grade, non-hematologic toxicity: CTCAE ≥ 2). No DLT other than d8 neutropenia was observed. The MTD was defined at 100 mg for the given day 1 and 8 schedule. Further related adverse events (AE’s) were of mild to moderate intensity (CTCAE grade ≤ 2). There were no related AEs resulting in study discontinuation. Preliminary PK analysis showed dose proportionality of C max and AUC 0-∞ with a high clearance (∼ 1500 mL/min) and a high volume of distribution (∼ 2000 L). No accumulation from d1 to d8 occurred. Patients were treated for up to 8 courses without evidence of accumulating toxicity. No objective responses were observed according to RECIST criteria in this heavily pretreated patient population. Conclusions: In summary BI 2536 is a Plk1 inhibitor with a favorable PK and safety profile at the tested dose and schedule. Neutropenia as a mechanism-related toxicity indicates target inhibition in vivo. [Table: see text]
PREGNANCY IN WOMEN WITH HEART DISEASE: IMPACT OF OBESITY ON MATERNAL AND FETAL OUTCOMES
Authors: Birgit Pfaller, Samuel Siu, Govind Krishna Kumar Nair, Barbara Wichert-Schmitt, Kim Haberer, Cynthia Maxwell, Rohan D'Souza, Candice K. Silversides
Journal: Journal of the American College of Cardiology (2020)
DIFFERENTIAL EFFICACY OF A NEW MAGNESIUM-BASED BIORESORBABLE STENT IN CHRONIC AND ACUTE CORONARY SYNDROMES
Authors: Stephane Carlier, Chadi Ghafari, Philippe Delmotte, Nicolas Brassart, Kaoru Tanaka, Kathleen Thayse, Philippe Brunner
Journal: Journal of the American College of Cardiology (2020)
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Authors: Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Munoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J. Kim, Lianqing Zheng, John M. Rossi, Frederick L. Locke
Journal: Blood (2020)
Longitudinal survey of microbiome associated with particulate matter in a megacity
Authors: Nan Qin, Peng Liang, Chunyan Wu, Guanqun Wang, Qian Xu, Xiao Xiong, Tingting Wang, Moreno Zolfo, Nicola Segata, Huanlong Qin, Rob Knight, Jack A. Gilbert, Ting F. Zhu
Journal: Genome biology (2020)

Abstract Background While the physical and chemical properties of airborne particulate matter (PM) have been extensively studied, their associated microbiome remains largely unexplored. Here, we performed a longitudinal metagenomic survey of 106 samples of airborne PM 2.5 and PM 10 in Beijing over a period of 6 months in 2012 and 2013, including those from several historically severe smog events. Results We observed that the microbiome composition and functional potential were conserved between PM 2.5 and PM 10 , although considerable temporal variations existed. Among the airborne microorganisms, Propionibacterium acnes , Escherichia coli , Acinetobacter lwoffii , Lactobacillus amylovorus , and Lactobacillus reuteri dominated, along with several viral species. We further identified an extensive repertoire of genes involved in antibiotic resistance and detoxification, including transporters, transpeptidases, and thioredoxins. Sample stratification based on Air Quality Index (AQI) demonstrated that many microbial species, including those associated with human, dog, and mouse feces, exhibit AQI-dependent incidence dynamics. The phylogenetic and functional diversity of air microbiome is comparable to those of soil and water environments, as its composition likely derives from a wide variety of sources. Conclusions Airborne particulate matter accommodates rich and dynamic microbial communities, including a range of microbial elements that are associated with potential health consequences.
36P Eligibility and outcomes in phase I clinical trials testing targeted therapy, immunotherapy and combinations: A single-institution study
Authors: A. Marra, S. Morganti, G. Viale, P. Tarantino, D. Trapani, E. Ferraro, P. Zagami, M. Repetto, E. Nicolò, P. D'Amico, P. Trillo Aliaga, M.A. Massaro, C. Busacca, I. Minchella, C. Belli, M. Locatelli, L. Mazzarella, A. Esposito, C. Criscitiello, G. Curigliano
Journal: Annals of Oncology (2020)
Assessment of Patient Ambulation Profiles to Predict Hospital Readmission, Discharge Location, and Length of Stay in a Cardiac Surgery Progressive Care Unit
Authors: In cheol Jeong, Ryan Healy, Benjamin Bao, William Xie, Tim Madeira, Marc Sussman, Glenn Whitman, Jennifer Schrack, Nicole Zahradka, Erik Hoyer, Charles Brown, Peter C. Searson
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Promoting patient mobility during hospitalization is associated with improved outcomes and reduced risk of hospitalization-associated functional decline. Therefore, accurate measurement of mobility with high–information content data may be key to improved risk prediction models, identification of at-risk patients, and the development of interventions to improve outcomes. Remote monitoring enables measurement of multiple ambulation metrics incorporating both distance and speed. <h3>Objective</h3> To evaluate novel ambulation metrics in predicting 30-day readmission rates, discharge location, and length of stay using a real-time location system to continuously monitor the voluntary ambulations of postoperative cardiac surgery patients. <h3>Design, Setting, and Participants</h3> This prognostic cohort study of the mobility of 100 patients after cardiac surgery in a progressive care unit at Johns Hopkins Hospital was performed using a real-time location system. Enrollment occurred between August 29, 2016, and April 4, 2018. Data analysis was performed from June 2018 to December 2019. <h3>Main Outcomes and Measures</h3> Outcome measures included 30-day readmission, discharge location, and length of stay. Digital records of all voluntary ambulations were created where each ambulation consisted of multiple segments defined by distance and speed. Ambulation profiles consisted of 19 parameters derived from the digital ambulation records. <h3>Results</h3> A total of 100 patients (81 men [81%]; mean [SD] age, 63.1 [11.6] years) were evaluated. Distance and speed were recorded for more than 14 000 segments in 840 voluntary ambulations, corresponding to a total of 127.8 km (79.4 miles) using a real-time location system. Patient ambulation profiles were predictive of 30-day readmission (sensitivity, 86.7%; specificity, 88.2%; C statistic, 0.925 [95% CI, 0.836-1.000]), discharge to acute rehabilitation (sensitivity, 84.6%; specificity, 86.4%; C statistic, 0.930 [95% CI, 0.855-1.000]), and length of stay (correlation coefficient, 0.927). <h3>Conclusions and Relevance</h3> Remote monitoring provides a high–information content description of mobility, incorporating elements of step count (ambulation distance and related parameters), gait speed (ambulation speed and related parameters), frequency of ambulation, and changes in parameters on successive ambulations. Ambulation profiles incorporating multiple aspects of mobility enables accurate prediction of clinically relevant outcomes.
EVALUATION OF A NEW SCATTER RADIATION REDUCTION AND ERGONOMIC SUPPORT SYSTEM IN A HIGH-VOLUME, PERCUTANEOUS CORONARY DIAGNOSIS AND INTERVENTION LABORATORY
Authors: Parloop Bhatt, Vipul Kapoor, Milan Chag, Satya Gupta, Anish Chandarana, Parth Parikh, Apurva Patel, Roosha Parikh, Hemang Baxi, Urmil Shah, Aditi Nanavati, Piyush Thakar, Tejas Patel, Keyur Parikh
Journal: Journal of the American College of Cardiology (2020)
Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011.
Authors: Sean Whittaker, Pablo L. Ortiz-Romero, Reinhard Dummer, Annamari Ranki, Baktiar Hasan, Bart Meulemans, Sylke Gellrich, Robert Knobler, Rudolf Stadler, Emad Shash
Journal: Journal of Clinical Oncology (2012)

8076 Background: Skin-directed treatment with methoxsalen (PUVA) is the current treatment standard in stage IB-IIA MF. A combination of PUVA and bexarotene might be of additional clinical benefit for MF stage I/II patients (pts). Methods: EORTC 21011 was a randomised, open label phase III study comparing combined bexarotene and PUVA versus PUVA alone in pts with stage IB and IIA MF. Study primary endpoint was response (complete clinical + partial response, CCR+PR) rate; secondary endpoints: cumulative dose of UVA and number of PUVA sessions necessary to achieve a CCR, duration of CCR, time to relapse, safety and percentage of drop-outs. Results: The study recruited stage IB/IIA MF pts and was prematurely closed due to low accrual after 93/145 required pts (65%) were randomized; 45 to PUVA, 48 to PUVA+bexarotene. Median number of PUVA weeks were 12 (1-17) in PUVA vs. 10.5 (1-16) in combination arm. Total UVA doses were 107J/cm2 (1.4-489.9) in PUVA vs. 101.7J/cm2 (0.2-529.9) in combination arm. Few grade 3-4 toxicities were observed in both arms (liver enzyme elevation, neutropenia, anemia, increased cholesterol, photosensitivity, pruritus, rash, hypertriglyceridemia). Best overall response (CCR/PR) rate was 71.1% (33/45) for PUVA alone and 77.1% (37/48) for combination arm (p-value=0.57). The median of duration of response was 9.6 for PUVA vs 5.8 months for combination arm (p value=0.33). CCR was seen in 25 pts, 10 in PUVA (CCR 24%) and 15 in combination therapy (CCR 33%) (pvalue=0.45). Similarily, a lower UVA dose was required to achieve a CCR in the combination arm (median of 55.8 J/cm2) compared to the PUVA arm (median of 117.58 J/cm2) (p value=0.5). Conclusions: No significant difference in response rate was observed in this study. There was a trend towards fewer PUVA sessions and lower UVA dose to achieve CCR in the PUVA/bexarotene combination arm (median of 27.5 vs. 22,p-value = 0.11) but this did not achieve statistical significance due to insufficient power. The safety profile was acceptable, as there were only few grade 3-4 toxicities observed in both arms.
QIM20-121: Oncology Nursing Evidenced Practice and Research Committee; Enhancing Continuity and Improving Patient Outcomes Across Oncology Service Lines
Authors: Kristen Burns, Archana Shenoy, Nicole Turkoglu
Journal: Journal of the National Comprehensive Cancer Network (2020)

"QIM20-121: Oncology Nursing Evidenced Practice and Research Committee; Enhancing Continuity and Improving Patient Outcomes Across Oncology Service Lines" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Abstract 17177: Gender Differences in Circulating Biomarkers After Lung Transplantation
Authors: Lourdes Chacon, Gabriel Loor, Daoud Daoud, Helen Andersson, Hassan Virk, Natalie Debolske, Hyewon Choi, Peter Jindra, Matthew Cusick, Luiz Sampaio, Doris A Taylor
Journal: Circulation (2019)

Background: Previous studies have linked inflammatory response after lung transplant (Tx) with development of primary graft dysfunction (PDG). The recipient’s baseline immune system and reperfusion...
From pests to tests: training rats to diagnose tuberculosis
Authors: Lena Fiebig, Negussie Beyene, Robert Burny, Cynthia D. Fast, Christophe Cox, Georgies F. Mgode
Journal: European Respiratory Journal (2020)

2020 is the year of the rat. The rat is the first of the 12 Chinese zodiac signs, and represents spirit, alertness, flexibility and vitality. In respiratory medicine, we may think of rats as vectors for diseases, such as pulmonary forms of hantavirus disease or leptospirosis, and pneumonic plague. Rodent control is thus part of hygiene guidelines and the International Health Regulations. And yet, the rat's keen sense of smell has led to its incredible career as a living tuberculosis (TB) detector. It's time… to find and treat all patients with TB. Rats may have a say in research towards better diagnostic tests. <http://bit.ly/2Rioa9N> The authors thank all study participants, clinicians, laboratory and rat handler teams, as well as all partners and donors who enabled the research into training and using TB detection rats. Main partners include the Sokoine University of Agriculture, the National Institute for Medical Research, MKUTA, and the National TB and Leprosy Programme in Tanzania; the University Eduardo Mondlane, the National Institute of Health, Associação Kenguelekezé, the Maputo City Health Authorities and the National TB Program in Mozambique; the Armauer Hansen Research Institute, the German Leprosy and TB Relief Association, the Prison Health Authorities and the National TB Program of Ethiopia; as well as the Technical University Braunschweig and Max Planck Institute for Infection Biology in Germany, and the University of Antwerp, Belgium.
EPICARDIAL ADIPOSE TISSUE PREDICTS THE PRESENCE OF AORTIC VALVE STENOSIS
Authors: Sara Akbar, Jasjit Bhinder, Nicole Zagelbaum, Syed Zaid, Hasan Ahmad, Joshua Goldberg, Joanne Bennett, Gilbert Tang, Daniel Spevack, Corazon Delapena, Tanya Dutta
Journal: Journal of the American College of Cardiology (2020)
RISK FACTORS FOR VENTRICULAR TAHCYARRHYTHMIC EVENTS IN PATIENTS WITHOUT LEFT BUNDLE BRANCH BLOCK WHO RECEIVE CARDIAC RESYNCHRONIZATION THERAPY
Authors: Arwa Younis, Mehmet Aktas, Alon Barsheshet, Spencer Rosero, David Huang, Wojciech Zareba, Scott McNitt, Valentina Kutyifa, Ilan Goldenberg
Journal: Journal of the American College of Cardiology (2020)
Early detection of lung cancer based on three-dimensional, morphometric analysis of cells from sputum following x-ray CT screening.
Authors: Terry Francis Urbine, Michael Meyer, Anna Tourovskaia, David Steinhauer, Jon Hayenga, Chris Presley, Ben Hawthorne, Thomas Neumann, Alan Nelson
Journal: Journal of Clinical Oncology (2012)

e17529 Background: A major advance against lung cancer was made with the announcement of results from the National Lung Cancer Screening Trial. A 20% reduction in mortality was shown in a screened population using low dose CT (LDCT) compared to screened chest x-rays. Approximately 95% of the positive findings of LDCT, however, turned out not to be cancer. We propose to use 3D morphometric analysis of cells from enriched sputum to distinguish benign from malignant nodules found using LDCT and to identify cancers that were not identified with LDCT. Methods: Sputum from 30 patients with non-small cell lung cancer were studied. Fluorescence activated cell sorting was used to enrich sputum for epithelial cells. The enriched cells, stained with hematoxylin, were automatically imaged using VisionGate’s 3D cell imaging system (Cell-CT) which unambiguously renders individual cells with isometric, sub-micron resolution. Image libraries of cells were created and 530 morphology features were computed for each cell. Abnormal (moderate and severe dysplasia and cancer) status for each cell was determined by a cytotechnologist and added to the feature set. Cross-validated classifiers were created that combine a sub-set of the features into a single score that best correlated with the binary cell diagnoses. Results: Study of enriched sputum from cancer patients using the Cell-CT shows cancer cells in at least 75% of the cases with cancer cells present in raw sputum. Classifier cell specificity exceeding 98% and a 70% cancer cell detection rate were measured. A 70% cell detection rate translates into a 90% detection rate for the specimen since multiple abnormal cells are present in sputum. Overall detection rate for cancer cell positive sputum is: 68%, computed by finding the product of the rate of cancer cell positive enriched sputum (0.75) with the rate of detection by the classifier (0.90). Conclusions: Automated, 3D morphometric analysis of cells from sputum provides high sensitivity and specificity detection of lung cancer. Adjunctive use with LDCT will aid in determination of the malignancy status of indeterminate pulmonary nodules.
PROGNOSTIC IMPLICATIONS OF ABSENCE OF CORONARY ARTERY CALCIUM IN ASYMPTOMATIC INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Tanuja Rajan, Reed Mszar, Shozab Siddiq Ali, Rana H. Asif, Miguel Cainzos-Achirica, Michael Blaha, Ron Blankstein, Salim Virani, Mouaz Al-Mallah, Marcio Bittencourt, Nasir Khurram
Journal: Journal of the American College of Cardiology (2020)
The expression of multiple proteins as prognostic factors in human colorectal cancer: The correlation between cathepsin D, p53, Cox-2, EGFR, C-erbB2, and Ki-67 expression.
Authors: In Kyu Lee, Hyung Jin Kim
Journal: Journal of Clinical Oncology (2012)

502 Background: This study aimed to establish a correlation between the expression of cathepsin D; p53; Cox-2; EGFR; C-erbB2; Ki-67 protein and the prognosis of colorectal cancer patients. Methods: Tissue samples were collected from 266 patients who underwent surgery for colorectal cancer from January 2006 to December 2007. The expression of the six proteins was determined using immunohistochemical staining of paraffin-embedded tissue specimens. Results: Cathepsin D, p53, Cox-2, EGFR, C-erbB2, and Ki-67 expression was detected in 38.7%, 60.9%, 37.6%, 35.7%, 30.1%, and 74.4% of the samples, respectively. The expression of cathepsin D was significantly correlated with reduced cancer-free survival (p=0.036) and overall survival (p=0.003), whereas the expression of the other proteins could not be correlated. In a multivariate analysis, after adjusting for age, sex, and stage, cathepsin D expression was found to be an independent prognostic factor for a short overall survival(HR=8.55, 95% CI 1.07–68.49). Furthermore, patients with tumors expressing four or more of the proteins had a significantly decreased cancer-free survival rate (p=0.006) and overall survival rate (p=0.002), when compared with patients expressing fewer than four of the proteins Conclusions: In this study, the expression of CD was correlated with a poor prognosis in terms of the cancer-free survival and the overall survival rate. Importantly, the high hazard ratio (HR=8.55) associated with CD expression from the multivariate analysis, even after adjusting for the tumor stage, demonstrates its potential as an independent, single-gene prognostic factor. The expression of four or more of the examined proteins was significantly correlated with a poor prognosis, even after adjusting for the stage. Currently, the prognostic value of a single gene marker in CRCA is very controversial, but based on these results, we believe that the number of expressed genes/proteins may be helpful in identifying patients with both early-stage cancer and a potentially poor prognosis, which will help to determine if adjuvant chemotherapy is necessary.